Higher immunogenicity of CD40L-transduced CLL cells compared with CD40-stimulated CLL cells (CD40-CLL) shown by IFN-γ ELISPOT assays
Sample, antigen specificity as tested in ELISPOT assay, and type of stimulation for T-cell expansion . | ELISPOT, d35 . |
|---|---|
| CLL-1 | |
| MDM2 | |
| CD40L-AAV | 8065 |
| GFP-AAV | 0 |
| CD40-CLL | 0 |
| p53 | |
| CD40L-AAV | 534 |
| GFP-AAV | 0 |
| CD40-CLL | 0 |
| CLL-2 | |
| Survivin | |
| CD40L-AAV | 3137 |
| GFP-AAV | 1646 |
| CD40-CLL | 1455 |
| KW-13 | |
| CD40L-AAV | 4750 |
| GFP-AAV | 984 |
| CD40-CLL | 616 |
| Fibromodulin | |
| CD40L-AAV | 4287 |
| GFP-AAV | 859 |
| CD40-CLL | 0 |
| CLL-3 | |
| MDM2 | |
| CD40L-AAV | 2280 |
| GFP-AAV | 680 |
| Native CLL | 840 |
| Fibromodulin | |
| CD40L-AAV | 1080 |
| GFP-AAV | 220 |
| Native CLL | 260 |
| p53 | |
| CD40L-AAV | 479 |
| GFP-AAV | 320 |
| Native CLL | 120 |
| CLL-4 | |
| MDM2 | |
| CD40L-AAV | 1800 |
| GFP-AAV | 485 |
| Native CLL | 0 |
| Fibromodulin | |
| CD40L-AAV | 2920 |
| GFP-AAV | 730 |
| Native CLL | 210 |
| CLL-5 | |
| MDM2 | |
| CD40L-AAV | 198 |
| GFP-AAV | 110 |
| Native CLL | 0 |
Sample, antigen specificity as tested in ELISPOT assay, and type of stimulation for T-cell expansion . | ELISPOT, d35 . |
|---|---|
| CLL-1 | |
| MDM2 | |
| CD40L-AAV | 8065 |
| GFP-AAV | 0 |
| CD40-CLL | 0 |
| p53 | |
| CD40L-AAV | 534 |
| GFP-AAV | 0 |
| CD40-CLL | 0 |
| CLL-2 | |
| Survivin | |
| CD40L-AAV | 3137 |
| GFP-AAV | 1646 |
| CD40-CLL | 1455 |
| KW-13 | |
| CD40L-AAV | 4750 |
| GFP-AAV | 984 |
| CD40-CLL | 616 |
| Fibromodulin | |
| CD40L-AAV | 4287 |
| GFP-AAV | 859 |
| CD40-CLL | 0 |
| CLL-3 | |
| MDM2 | |
| CD40L-AAV | 2280 |
| GFP-AAV | 680 |
| Native CLL | 840 |
| Fibromodulin | |
| CD40L-AAV | 1080 |
| GFP-AAV | 220 |
| Native CLL | 260 |
| p53 | |
| CD40L-AAV | 479 |
| GFP-AAV | 320 |
| Native CLL | 120 |
| CLL-4 | |
| MDM2 | |
| CD40L-AAV | 1800 |
| GFP-AAV | 485 |
| Native CLL | 0 |
| Fibromodulin | |
| CD40L-AAV | 2920 |
| GFP-AAV | 730 |
| Native CLL | 210 |
| CLL-5 | |
| MDM2 | |
| CD40L-AAV | 198 |
| GFP-AAV | 110 |
| Native CLL | 0 |
T cells from patients with CLL were expanded using autologous CD40L-transduced (CD40L-AAV), GFP-transduced (GFP-AAV), CD40-stimulated (CD40-CLL), and native CLL cells as APCs. IFN-γ ELISPOT assays were performed on day 35 (d35). Given are the numbers of TAA-specific spots per 100 000 T cells. APCs in the IFN-γ ELISPOT assay corresponded to the APCs used for the stimulation of T cells.